• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Infect Chemother . Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19

tetano

Editor, Senior Moderator
J Infect Chemother


. 2021 Jan 18;S1341-321X(21)00014-3.
doi: 10.1016/j.jiac.2021.01.006. Online ahead of print.
Factors associated with anti-SARS-CoV-2 IgG antibody production in patients convalescing from COVID-19


Satoshi Kutsuna[SUP] 1 [/SUP], Yusuke Asai[SUP] 2 [/SUP], Akihiro Matsunaga[SUP] 3 [/SUP], Noriko Kinoshita[SUP] 4 [/SUP], Mari Terada[SUP] 4 [/SUP], Yusuke Miyazato[SUP] 4 [/SUP], Takato Nakamoto[SUP] 4 [/SUP], Tetsuya Suzuki[SUP] 4 [/SUP], Sho Saito[SUP] 5 [/SUP], Mio Endo[SUP] 2 [/SUP], Kohei Kanda[SUP] 4 [/SUP], Maeda Kenji[SUP] 6 [/SUP], Jin Takasaki[SUP] 7 [/SUP], Masayuki Hojo[SUP] 7 [/SUP], Yukihito Ishizaka[SUP] 8 [/SUP], Norio Ohmagari[SUP] 4 [/SUP]



Affiliations

Abstract

Introduction: Among patients with coronavirus disease 2019 (COVID-19), the factors that affect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody production remain unclear. This study aimed to identify such factors among patients convalescing from COVID-19.
Methods: This study comprised patients who had been diagnosed with COVID-19 between January 1 and June 30, 2020 and gave consent for anti-SARS-CoV-2 spike protein antibody measurement using enzyme-linked immunosorbent assay during their acute and/or convalescent phases. Factors related to elevated antibody titers and the relationship between the days from disease onset and the development of antibody titers were assessed.
Results: A total of 84 participants enrolled in the study. Nineteen participants had antibody titers measured during the convalescent phase only, and 65 participants had antibody titers measured during the acute and convalescent phases. The antibody titers peaked in weeks 5 and 6. The stepwise multivariate log-normal analysis revealed that male sex (P = 0.04), diabetes mellitus (P = 0.03), and high C-reactive protein levels during the disease course (P < 0.001) were associated with elevated IgG antibodies. Glucocorticoid use was not associated with antibody titers.
Conclusion: The study found that high values of maximum CRP levels during the acute phase, male sex, and diabetes mellitus were associated with elevated antibody titers. Antibody titers tended to be highest in the first 5 or 6 weeks after the onset of symptoms.

Keywords: Anti-SARS-CoV-2 spike protein antibody; COVID-19; Convalescent; SARS-CoV-2.
 
Back
Top Bottom